Last reviewed · How we verify
Ondanesterone plus dexamethasone combination
Ondanesterone plus dexamethasone combination, marketed by Aiman Al-Touny, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's key strength lies in its unique combination therapy, which may offer distinct advantages over monotherapy options. The primary risk is the lack of detailed revenue data and key trial results, which could impact investor confidence and market adoption.
At a glance
| Generic name | Ondanesterone plus dexamethasone combination |
|---|---|
| Sponsor | Aiman Al-Touny |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: